Get started
Author

Lisa La

A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma
2017 · Ajai Chari, Hearn J. Cho, et al. · Blood Advances · 60
PDF
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma
2020 · Oliver Van Oekelen, Samir Parekh, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 16
A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma
2015 · Ajai Chari, Hearn Jay Cho, et al. · Blood · 16
A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat In Combination With Lenalidomide and Weekly Dexamethasone In Patients With Multiple Myeloma
2013 · Noa Biran, Samira Shahnaz, et al. · Blood · 9
A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.
2015 · Ajai Chari, Hearn J. Cho, et al. · Journal of Clinical Oncology · 7
Predictors for inpatient mortality during the first wave of the SARS-CoV-2 pandemic: A retrospective analysis
2021 · Daniel Sammartino, Farrukh Jafri, et al. · PLoS ONE · 5
PDF
A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
2016 · Ajai Chari, Hearn Jay Cho, et al. · Blood · 4
Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect® MM Registry
2020 · Lisa La, Sundar Jagannath, et al. · Blood · 3
Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
2017 · Keren Osman, Ajai Chari, et al. · Transplantation and Cellular Therapy · 3
Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib
2015 · Ajai Chari, Hearn Jay Cho, et al. · Blood · 3
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2
2019 · Kevin Barley, Larysa Sanchez, et al. · American Journal of Hematology · 2
PDF
A Phase II, Single-Center, Open-Label Study of Oral Panobinostat in Combination with Lenalidomide and Weekly Dexamethasone in Patients with Multiple Myeloma
2014 · Ajai Chari, Hearn J. Cho, et al. · Blood · 2
The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.
2010 · Sandra Wear, Paul G. Richardson, et al. · Blood · 2
Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
2016 · Keren Osman, Ajai Chari, et al. · Blood · 1
Are two sites better than one?: Sites of care and quality of myeloma treatment.
2019 · Anne Renteria, Sundar Jagannath, et al. · Journal of Clinical Oncology
Racial and insurance disparities in multiple myeloma management in a referral center.
2019 · Anne Renteria, Sundar Jagannath, et al. · Journal of Clinical Oncology
Phase 1 Study of Elotuzumab and Peripheral Blood Mononuclear Cell Reconstitution in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
2017 · Keren Osman, Ajai Chari, et al. · Blood
The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development
2011 · Sandra M. Wear, Paul G. Richardson, et al. · Blood
Works count: 18
Citation count: 133
H-index: 5
I10-index: 3
Year
Topic
Type